A PROSPECTIVE, PHASE 2, COMPARATIVE STUDY OF ORAL SCY-078 VS. STANDARD-OF-CARE FOLLOWING INTRAVENOUS ECHINOCANDIN THERAPY IN THE TREATMENT OF INVASIVE CANDIDIASIS (INCLUDING CANDIDEMIA)

被引：0
|
作者：
Pappas, Peter [1 ]
Helou, Silvia [2 ]
Angulo, David [2 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Scynexis Inc, Jersey City, NJ USA
来源：
TRANSPLANT INTERNATIONAL | 2017年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
BOS511
引用
收藏
页码：311 / 311
页数：1
相关论文
共 2 条
  • [1] MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis
    Spec, Andrej
    Pullman, John
    Thompson, George R., III
    Powderly, William G.
    Tobin, Ellis H.
    Vazquez, Jose
    Wring, Stephen A.
    Angulo, David
    Helou, Silvia
    Pappas, Peter G.
    Ostrosky-Zeichner, Luis
    Patterson, Thomas
    Alexander, Barbara
    Boucher, Helen
    Pappas, Peter
    Betts, Robert
    Schuster, Mindy
    Shoham, Shmuel
    Revankar, Sanjay
    Mushatt, David
    Bedimo, Roger
    Freifeld, Alison
    Nguyen, Minh Hong
    Mylonakis, Eleftherios
    Kett, Daniel
    Reboli, Annette
    Walsh, Thomas
    Pouch, Stephanie
    Almyroudis, Nikolaos
    Andes, David
    Hadley, Susan
    Barron, Michelle
    Mullane, Katheen
    Miller, Loren
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (10) : 3056 - 3062
  • [2] HERIZON-BTC-302: A phase 3 study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC).
    Harding, James J.
    Macarulla, Teresa
    Pant, Shubham
    Wu, Xiaotian
    Garfin, Phillip M.
    Okusaka, Takuji
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS648 - TPS648
1